Systemic Diseases and Syndromes that Affect the Periodontium

Board takeaway

• Recognize: Investigate systemic causes when a child has rapid periodontal destruction or premature tooth loss.
• Differentiate: Match the dental pattern with immune, skin, skeletal, metabolic, and family-history findings, then coordinate assessment and care.
• Coordinate: Medical status determines infection precautions, bleeding management, timing, and rehabilitation.
• Scope: This reference chart supports the differential and individualized prevention; it does not supply a universal treatment or recall protocol.
• SRP means scaling and root planing.

Recognize the referral-changing pattern

Chédiak-Higashi syndrome

• Autosomal recessive immune disorder: reduced pigmentation, neurologic deficits, fever, lymphadenopathy, hepatosplenomegaly, anemia, neutropenia, and thrombocytopenia.
• Chart describes mild atypical disease in 10–15% and classic disease in 80–90%; the classic accelerated phase is fatal without bone marrow transplantation.
• Diagnostic workup: white-cell microscopy and genetic testing for LYST/CHS1 mutations.
• Severe inflammation, swelling, recession, possible ulcers, and early periodontitis in both dentitions; premature loss with localized/generalized bone loss.
• Coordinate timing and precautions with immune/transplant status; treat bacterial infections supportively. Recurrent aggressive disease may resist SRP and antibiotics.
• For surgery/extractions, consider additional hemostatic measures; avoid NSAIDs because of platelet dysfunction. Prostheses depend on medical status.

Diabetes mellitus

• Type 1: autoimmune loss of insulin production; type 2: insulin resistance; gestational diabetes: pregnancy-associated insulin resistance.
• Increased inflammation and impaired immune response/healing accompany cardiovascular, retinal, renal, and neurologic complications.
• Tests listed: A1C, oral glucose tolerance, fasting plasma glucose, and random plasma glucose. No diagnostic or dental-treatment cutoff is supplied.
• Enlarged erythematous attached gingiva, dental/periodontal abscesses, pockets, attachment loss, and severe periodontitis with alveolar loss.
• Assess control, including diet and medication adherence. For uncontrolled diabetes, the chart says to consider prophylactic antibiotics for invasive procedures.
• Nonsurgical periodontal treatment, including SRP and antimicrobial agents, may provide modest glycemic improvement. Monitor for delayed healing.

Papillon Lefèvre and Haim-Munk syndromes

• Papillon Lefèvre syndrome (PLS): autosomal recessive CTSC/cathepsin C disorder, with likely neutrophil defects. Palmoplantar hyperkeratosis, nail dystrophy, pyogenic infections, and intracranial calcification are listed.
• Periodontal destruction begins soon after eruption in both dentitions: bleeding/inflammation, deep pockets, abscesses, extensive generalized bone loss, and tooth migration.
• Chart describes loss of all primary teeth by ages 4–5 and permanent teeth by age 16; gingiva becomes healthy after tooth loss. These describe the disease pattern, not an extraction timetable.
• PLS diagnostic entries include genetic testing and urine testing for cathepsin C activity; periodontal degeneration is a key clinical clue.
• Haim-Munk: autosomal recessive PLS variant with cathepsin C loss of function; comparatively milder periodontal disease but more severe skin manifestations. Genetic testing identifies the mutation.
• Additional clues: scaly facial patches, skin infections, arachnodactyly, curved/thickened nails, distal bone resorption, flat feet, contractures, and destructive arthritis. The chart gives the same destructive dental pattern and tooth-loss ages as PLS.
• For either syndrome, plan around age, psychological status, and mobility. Options may include monthly SRP, systemic antibiotics, and/or removal of hopeless teeth. Extensive alveolar loss complicates prosthetic rehabilitation.

Hypophosphatasia

• ALPL mutations cause low alkaline phosphatase activity and impaired bone/tooth mineralization. Six types span different onset ages and severity; multisystem complications vary.
• Cementum formation is disturbed. Early primary-tooth exfoliation with little or no root resorption may be an initial sign; inflammation can be relatively mild.
• Diagnostic assessment: serum alkaline phosphatase and ALPL testing.
• Radiographs may show alveolar loss, enlarged pulp chambers/canals, and thin dentin. Mild subtypes may have normal permanent dentitions; severe disease can produce periodontitis and early loss.
• Enzyme replacement has shown periodontal, dental, and skeletal improvement; the chart does not quantify benefit or establish a regimen.
• Exercise orthodontic caution because attachment and cementum are impaired. Removable prostheses are options; implants to stabilize a permanent-dentition prosthesis may be considered after skeletal maturity.

Langerhans cell histiocytosis

• Inflammatory myeloid neoplasia with histiocyte proliferation/infiltration; distinguish single-system from multisystem disease. Typical onset is ages 1–3, with male predominance.
• Chart reports mortality below 10% for single-system versus 30–50% for multisystem disease; these broad figures are not individual prognoses.
• Oral pain, gingivitis/bleeding, recession, swelling, ulceration, mobility, and early exfoliation may be presenting signs.
• Bone destruction can produce a floating-teeth appearance; jaw lesions may be solitary or multiple.
• Diagnosis uses clinical, microscopic, hematologic, and imaging assessment.
• Periodontal therapy alone is not first-line disease treatment. Depending on extent/type, lesion management ranges from observation to drugs, excision/curettage, and/or radiation.
• Include basic periodontal care and extraction of hopeless teeth as immune status permits.

Leukocyte adhesion deficiency syndromes

• Autosomal recessive immunodeficiencies with impaired white-cell migration, recurrent bacterial/fungal mucosal infections without pus, and poor healing.
• Key combination: leukocytosis plus absent pus. Diagnostic testing includes genetics and flow cytometry of neutrophil expression.
• Severe rapidly progressive periodontitis, persistent ulcers, alveolar loss, and early loss of both dentitions; meticulous home care and nonsurgical treatment may still fail.
• Chart lists prompt targeted antibiotics and prophylactic antibiotics before dental procedures. Coordinate adjunctive care with specialists: granulocyte/platelet transfusions, recombinant factor VIIa, or intravenous immunoglobulin may be used.
• Hematopoietic stem-cell transplantation is identified as the only curative treatment; mortality is high.

Obesity

• Multifactorial excess adiposity; genetic, neuroendocrine, medication, diet, and activity factors contribute.
• Chart threshold for ages 2–19: BMI at/above the age- and sex-based CDC 95th percentile or 30 kg/m², whichever is lower. Adult threshold: 30 kg/m². Other measures include waist/hip circumferences and ratios.
• Associated findings: more plaque, bleeding on probing, deeper pockets, attachment/bone loss, and mouth breathing.
• Consider diabetes, hypertension, cardiovascular disease, obstructive sleep apnea, inflammation, and other comorbidities in management.
• Dietary weight reduction may lower systemic inflammation and improve periodontal-treatment response; benefit is not guaranteed.

Periodontal Ehlers-Danlos syndrome

• Autosomal dominant connective-tissue disorder, also termed pEDS or EDS VIII; C1R/C1S variants affect innate immunity.
• Clues: tissue fragility/easy bruising, vascular complications, joint hypermobility/pain, pretibial discoloration/plaques, infections, and hoarseness. Family history identifies many affected children.
• Severe early periodontitis, chart mean onset age 14; thin/receding gingiva, absent attached gingiva, rapid bone loss, and premature tooth loss.
• Clinical assessment plus molecular testing supports diagnosis. Complete lack of attached gingiva is considered pathognomonic, as clarified in the chart's cited GeneReviews source.
• Options may include monthly SRP, systemic antibiotics, and/or extraction of hopeless teeth. Bone loss complicates prostheses; implants carry high peri-implantitis risk.

Common board traps

Answer aloud

A preschooler loses primary teeth with largely intact roots. What guides your differential?

Consider hypophosphatasia and coordinate medical evaluation of mineralization.

• Early exfoliation with little/no resorption and relatively mild inflammation is a key clue.
• Assess alkaline phosphatase and ALPL testing with the medical team.
• Impaired cementum/attachment warrants orthodontic caution; possible implants require skeletal maturity.

Rapid periodontal destruction accompanies recurrent infections without pus. What next?

Consider leukocyte adhesion deficiency and coordinate immunologic evaluation and infection precautions.

• Leukocytosis plus absent pus is a major clue; genetic and neutrophil flow-cytometry testing support assessment.
• Local periodontal care may be refractory despite meticulous home care.
• Coordinate targeted antibiotics, procedure prophylaxis, and specialist-directed adjuncts.

How do invasive-care priorities differ in uncontrolled diabetes and Chédiak-Higashi syndrome?

Individualize precautions to metabolic control versus immune and platelet dysfunction.

These chart entries do not supply universal doses, blood-count limits, or A1C cutoffs.

How do skin findings and gingival anatomy distinguish Papillon Lefèvre syndrome from periodontal Ehlers-Danlos syndrome?

Use the pattern to direct medical/genetic assessment rather than diagnose from periodontal destruction alone.

• Hopeless teeth may require extraction; bone loss complicates rehabilitation.
• pEDS implants have high peri-implantitis risk.

A child's jaw radiograph shows a floating-teeth appearance. What changes the plan?

Consider Langerhans cell histiocytosis and pursue multidisciplinary diagnostic assessment.

• Correlate bone destruction with pain, swelling, ulceration, mobility, and early tooth loss.
• Clinical, microscopic, hematologic, and imaging assessment establishes the diagnosis.
• Periodontal therapy alone is not first-line disease treatment; lesion treatment depends on disease type/extent.